{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:27:47Z","timestamp":1790015267960,"version":"4.0.1"},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"44","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,31]]},"abstract":"<jats:p>Nifedipine, a dihydropyridine calcium channel blocker, is widely used in the management of hypertension and as a tocolytic agent to delay preterm labor, including in pregnant women. However, its safety profile, particularly in pregnant populations, remains insufficiently characterized. This study aimed to evaluate adverse event (AE) signals associated with nifedipine use, with a specific focus on pregnancy-related outcomes. Nifedipine-related AEs reported in U.S. Food and Drug Administration Adverse Event Reporting System database (Q1 2004\u2013Q4 2024) were analyzed. Disproportionality analysis was conducted using 4 established signal detection methods: reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian Confidence Propagation Neural Network, and Multi-item Gamma Poisson Shrinker. Pregnancy-related reports were identified using Standardized MedDRA Queries, and subgroup analyses were conducted for pregnant women. In the overall population, significant signals at the System Organ Class level were observed for pregnancy-related conditions, vascular disorders, and cardiac disorders. The strongest prominent preferred term signal was gingival hypertrophy (n\u2005=\u200552; ROR\u2005=\u2005100.55, PRR\u2005=\u2005100.23, information component [IC]\u2005=\u20056.61, empirical Bayesian geometric mean [EBGM]\u2005=\u200597.42). Among pregnant women, prominent signals at the System Organ Class level included vascular disorders, respiratory disorders, and cardiac disorders. The strongest preferred term signal was acute pulmonary edema (n\u2005=\u200527; ROR\u2005=\u200567.23, PRR\u2005=\u200566.70, IC\u2005=\u20055.87, EBGM\u2005=\u200558.29), followed by cardiogenic shock (n\u2005=\u200511; ROR\u2005=\u200541.80, PRR\u2005=\u200541.67, IC\u2005=\u20055.26, EBGM\u2005=\u200538.25), pulmonary edema (n\u2005=\u200551; ROR\u2005=\u200538.57, PRR\u2005=\u200538.00, IC\u2005=\u20055.14, EBGM\u2005=\u200535.15), and hypoxia (n\u2005=\u200528; ROR\u2005=\u200520.62, PRR\u2005=\u200520.46, IC\u2005=\u20054.29, EBGM\u2005=\u200519.62). Several unexpected pregnancy-related AEs were also detected, including eclampsia, fetal distress, placental disorders, and intrauterine growth restriction. This study identified unexpected AE signals associated with nifedipine use during pregnancy. The findings offer valuable insights to guide clinical decision-making and promote safer use of nifedipine in pregnant populations.<\/jats:p>","DOI":"10.1097\/md.0000000000045113","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T17:00:48Z","timestamp":1763571648000},"page":"e45113","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["A disproportionality analysis of nifedipine in the overall population and in pregnant women using the FDA Adverse Event Reporting System (FAERS) database"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-3725-5180","authenticated-orcid":false,"given":"Guangxin","family":"Ju","sequence":"first","affiliation":[{"name":"Shanxi Medical University, Taiyuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Chen","sequence":"additional","affiliation":[{"name":"Ordos Maternal and Child Health Hospital, Ordos, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruoxin","family":"Wang","sequence":"additional","affiliation":[{"name":"Harbin Medical University, Harbin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lusi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Shanxi Medical University, Taiyuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeyun","family":"Liu","sequence":"additional","affiliation":[{"name":"Shanxi Medical University, Taiyuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2852-5613","authenticated-orcid":false,"given":"Shaohui","family":"Chen","sequence":"additional","affiliation":[{"name":"Shanxi Maternal and Child Health Hospital, Taiyuan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260520","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003495-200666991-00002","article-title":"[Nifedipine: a novel vasodilator].","volume":"66 Spec No. 1","author":"Taira","year":"2006","journal-title":"Drugs"},{"key":"R2-20260520","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1002\/jps.24560","article-title":"Biowaiver monographs for immediate-release solid oral dosage forms: nifedipine.","volume":"104","author":"Gajendran","year":"2015","journal-title":"J Pharm Sci"},{"key":"R4-20260520","doi-asserted-by":"crossref","first-page":"737","DOI":"10.2165\/00003495-199141050-00006","article-title":"Sustained release nifedipine formulations. An appraisal of their current uses and prospective roles in the treatment of hypertension, ischaemic heart disease and peripheral vascular disorders.","volume":"41","author":"Murdoch","year":"1991","journal-title":"Drugs"},{"key":"R5-20260520","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.2174\/0115680266323908241114064318","article-title":"Updates on intrinsic medicinal chemistry of 1,4-dihydropyridines, perspectives on synthesis and pharmacokinetics of novel 1,4-dihydropyrimidines as calcium channel blockers: clinical pharmacology.","volume":"25","author":"Devi Sri","year":"2025","journal-title":"Curr Top Med Chem"},{"key":"R6-20260520","doi-asserted-by":"crossref","first-page":"497","DOI":"10.2165\/00003495-200666040-00007","article-title":"Modified-release nifedipine: a review of the use of modified-release formulations in the treatment of hypertension and angina pectoris.","volume":"66","author":"Croom","year":"2006","journal-title":"Drugs"},{"key":"R7-20260520","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s40292-023-00582-5","article-title":"Hypertension in pregnancy: a diagnostic and therapeutic overview.","volume":"30","author":"C\u00edfkov\u00e1","year":"2023","journal-title":"High Blood Pressure Cardiovascular Prevent"},{"key":"R9-20260520","doi-asserted-by":"crossref","first-page":"e19266","DOI":"10.2196\/19266","article-title":"Complementing the US food and drug administration adverse event reporting system with adverse drug reaction reporting from social media: comparative analysis.","volume":"6","author":"Zhou","year":"2020","journal-title":"JMIR Public Health Surveillance"},{"key":"R10-20260520","doi-asserted-by":"crossref","first-page":"e884","DOI":"10.1016\/S2352-3026(20)30327-6","article-title":"Safety of direct oral anticoagulant exposure during pregnancy: a retrospective cohort study.","volume":"7","author":"Beyer-Westendorf","year":"2020","journal-title":"Lancet Haematol"},{"key":"R11-20260520","doi-asserted-by":"crossref","first-page":"1063625","DOI":"10.3389\/fphar.2022.1063625","article-title":"Potential safety signal of pregnancy loss with vascular endothelial growth factor inhibitor intraocular injection: a disproportionality analysis using the food and drug administration adverse event reporting system.","volume":"13","author":"Sakai","year":"2022","journal-title":"Front Pharmacol"},{"key":"R12-20260520","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s40801-021-00287-y","article-title":"Pregnancy loss signal from prostaglandin eye drop use in pregnancy: a disproportionality analysis using japanese and US spontaneous reporting databases.","volume":"9","author":"Sakai","year":"2022","journal-title":"Drugs Real World Outcomes"},{"key":"R13-20260520","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s40264-017-0560-z","article-title":"Signal of Miscarriage with Aripiprazole: A Disproportionality Analysis of the Japanese Adverse Drug Event Report Database.","volume":"40","author":"Sakai","year":"2017","journal-title":"Drug Saf"},{"key":"R14-20260520","doi-asserted-by":"crossref","first-page":"11465","DOI":"10.1038\/s41598-019-47967-y","article-title":"Direct-acting oral anticoagulants (DOACs) in pregnancy: new insight from VigiBase(\u00ae).","volume":"9","author":"Sessa","year":"2019","journal-title":"Sci Rep"},{"key":"R15-20260520","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio.","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R16-20260520","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports.","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R17-20260520","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2165\/00002018-200225060-00002","article-title":"A data mining approach for signal detection and analysis.","volume":"25","author":"Bate","year":"2002","journal-title":"Drug Saf"},{"key":"R18-20260520","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jad.2023.11.025","article-title":"Safety assessment of Brexpiprazole: Real-world adverse event analysis from the FAERS database.","volume":"346","author":"Jiang","year":"2024","journal-title":"J Affect Disord"},{"key":"R19-20260520","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/17512433.2024.2306223","article-title":"Metformin adverse event profile: a pharmacovigilance study based on the FDA Adverse Event Reporting System (FAERS) from 2004 to 2022.","volume":"17","author":"Du","year":"2024","journal-title":"Expert Rev Clin Pharmacol"},{"key":"R21-20260520","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/jch.14436","article-title":"Comparative peripheral edema for dihydropyridines calcium channel blockers treatment: A systematic review and network meta-analysis.","volume":"24","author":"Liang","year":"2022","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"R22-20260520","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1097\/HJH.0b013e3283472643","article-title":"Peripheral edema associated with calcium channel blockers: incidence and withdrawal rate--a meta-analysis of randomized trials.","volume":"29","author":"Makani","year":"2011","journal-title":"J Hypertens"},{"key":"R24-20260520","first-page":"97","article-title":"Prevalence of calcium channel blocker induced ankle edema and its treatment in a cohort of newly diagnosed hypertensive patients.","volume":"7","author":"Onah","year":"2022","journal-title":"Int J Pharm Sci Med"},{"key":"R25-20260520","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s11886-002-0110-9","article-title":"Vasodilatory edema: a common side effect of antihypertensive therapy.","volume":"4","author":"Messerli","year":"2002","journal-title":"Curr Cardiol Rep"},{"key":"R26-20260520","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.amjmed.2010.08.007","article-title":"Effect of renin-angiotensin system blockade on calcium channel blocker-associated peripheral edema.","volume":"124","author":"Makani","year":"2011","journal-title":"Am J Med"},{"key":"R27-20260520","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/hr.2013.80","article-title":"Nifedipine controlled-release 40\u2009mg b.i.d. in Japanese patients with essential hypertension who responded insufficiently to nifedipine controlled-release 40\u2009mg q.d.: a phase III, randomized, double-blind and parallel-group study.","volume":"37","author":"Shimamoto","year":"2014","journal-title":"Hypert Res"},{"key":"R28-20260520","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/jhh.2013.47","article-title":"Calcium channel blocker-induced gingival enlargement.","volume":"28","author":"Livada","year":"2014","journal-title":"J Hum Hypertens"},{"key":"R29-20260520","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1902\/jop.1987.58.9.639","article-title":"Gingival hyperplasia caused by nifedipine. Histopathologic findings.","volume":"58","author":"Barak","year":"1987","journal-title":"J Periodontol"},{"key":"R30-20260520","first-page":"11","article-title":"Regression of calcium channel blocker--induced gingival enlargement in the absence of periodontal therapy.","volume":"95","author":"Livada","year":"2015","journal-title":"J Tenn Dent Assoc"},{"key":"R31-20260520","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0003-9969(94)90103-1","article-title":"Effect of calcium-channel blockers on cell proliferation, DNA synthesis and collagen synthesis of cultured gingival fibroblasts derived from human nifedipine responders and non-responders.","volume":"39","author":"Fujii","year":"1994","journal-title":"Arch Oral Biol"},{"key":"R32-20260520","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1600-051X.1996.tb02072.x","article-title":"The pathogenesis of drug-induced gingival overgrowth.","volume":"23","author":"Seymour","year":"1996","journal-title":"J Clin Periodontol"},{"key":"R33-20260520","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2334\/josnusd.21-0419","article-title":"Hepatocyte growth factor exhibits anti-fibrotic effects in an in vitro model of nifedipine-induced gingival overgrowth.","volume":"64","author":"Yamazaki","year":"2021","journal-title":"J Oral Sci"},{"key":"R34-20260520","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s11596-013-1104-0","article-title":"TGF-\u03b21-induced synthesis of collagen fibers in skeletal muscle-derived stem cells.","volume":"33","author":"Chen","year":"2013","journal-title":"J Huazhong Univ Sci Technol. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban"},{"key":"R35-20260520","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/jcp.20917","article-title":"Connective tissue growth factor (CTGF\/CCN2) is a downstream mediator for TGF\u2010\u03b21\u2010induced extracellular matrix production in osteoblasts.","volume":"210","author":"Arnott","year":"2007","journal-title":"J Cell Physiol"},{"key":"R37-20260520","doi-asserted-by":"crossref","first-page":"e0173191","DOI":"10.1371\/journal.pone.0173191","article-title":"Smad3-dependent CCN2 mediates fibronectin expression in human skin dermal fibroblasts.","volume":"12","author":"Purohit","year":"2017","journal-title":"PLoS One"},{"key":"R38-20260520","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.matbio.2019.01.002","article-title":"Denervation-induced skeletal muscle fibrosis is mediated by CTGF\/CCN2 independently of TGF-\u03b2.","volume":"82","author":"Rebolledo","year":"2019","journal-title":"Matrix Biol"},{"key":"R39-20260520","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1007\/s10753-015-0126-0","article-title":"Local inflammation alters MMP-2 and MMP-9 gelatinase expression associated with the severity of nifedipine-induced gingival overgrowth: a rat model study.","volume":"38","author":"Li","year":"2015","journal-title":"Inflammation"},{"key":"R40-20260520","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1177\/154405910808700614","article-title":"IL-1\u03b2 and TNF-\u03b1 regulate IL-6-type cytokines in gingival fibroblasts.","volume":"87","author":"Palmqvist","year":"2008","journal-title":"J Dent Res"},{"key":"R41-20260520","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1600-0765.2012.01500.x","article-title":"Comparison of CCL28, interleukin-8, interleukin-1\u03b2 and tumor necrosis factor-alpha in subjects with gingivitis, chronic periodontitis and generalized aggressive periodontitis.","volume":"48","author":"Ertu\u011frul","year":"2013","journal-title":"J Periodontal Res"},{"key":"R42-20260520","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1155\/2013\/948569","article-title":"Local and systemic inflammatory responses to experimentally induced gingivitis.","volume":"35","author":"Leishman","year":"2013","journal-title":"Dis Markers"},{"key":"R43-20260520","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/j.1600-0714.1996.tb00207.x","article-title":"Cyclosporin- and nifedipine-induced gingival overgrowth in renal transplant patients: correlations with periodontal and pharmacological parameters, and HLA-antigens.","volume":"25","author":"Margiotta","year":"1996","journal-title":"J Oral Pathol Med"},{"key":"R44-20260520","doi-asserted-by":"crossref","first-page":"14","DOI":"10.14295\/bds.2012.v15i4.836","article-title":"Nifedipine-Induced gingival overgrowth.","volume":"15","author":"Florio","year":"2013","journal-title":"Braz Dental Sci"},{"key":"R45-20260520","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1834-7819.2007.tb00505.x","article-title":"Clinical and pharmacological variables as a risk factor for nifedipine-induced gingival overgrowth.","volume":"52","author":"G\u00fcnc\u00fc","year":"2007","journal-title":"Aust Dent J"},{"key":"R46-20260520","doi-asserted-by":"crossref","first-page":"S191","DOI":"10.4103\/0975-7406.100268","article-title":"Nifedipine-induced gingival enlargement: Correlation with dose and oral hygiene.","volume":"4","author":"Sunil","year":"2012","journal-title":"J Pharm Bioallied Sci"},{"key":"R48-20260520","first-page":"1629","article-title":"Nifedipine effectiveness in treating hypertension disorders of pregnancy: a literature review.","volume":"5","author":"Fitri","year":"2024","journal-title":"Int J Sci Adv"},{"key":"R49-20260520","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/AOG.0000000000005613","article-title":"Pregnancy outcomes of nifedipine compared with labetalol for oral treatment of mild chronic hypertension.","volume":"144","author":"Sanusi","year":"2024","journal-title":"Obstetrics Gynecol"},{"key":"R50-20260520","doi-asserted-by":"crossref","first-page":"1225251","DOI":"10.3389\/fcvm.2023.1225251","article-title":"Antihypertensive medication use during pregnancy in a real-world cohort of patients diagnosed with a hypertensive disorder of pregnancy.","volume":"10","author":"Garcia","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"R51-20260520","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1517\/14656566.2014.889684","article-title":"Preterm labor: current pharmacotherapy options for tocolysis.","volume":"15","author":"van Vliet","year":"2014","journal-title":"Expert Opin Pharmacother"},{"key":"R52-20260520","doi-asserted-by":"crossref","first-page":"31","DOI":"10.4103\/aam.aam_11_20","article-title":"A Comparative study of transdermal nitroglycerine patch and oral nifedipine in preterm labor.","volume":"20","author":"Kaur","year":"2021","journal-title":"Ann Afr Med"},{"key":"R54-20260520","doi-asserted-by":"crossref","first-page":"544.e1","DOI":"10.1016\/j.ajog.2021.04.228","article-title":"Nifedipine disturbs fetal cardiac function during hypoxemia in a chronic sheep model at near term gestation.","volume":"225","author":"Alanne","year":"2021","journal-title":"Am J Obstet Gynecol"},{"key":"R55-20260520","doi-asserted-by":"crossref","first-page":"e0173717","DOI":"10.1371\/journal.pone.0173717","article-title":"Maintenance nifedipine therapy for preterm symptomatic placenta previa: a randomized, multicenter, double-blind, placebo-controlled trial.","volume":"12","author":"Verspyck","year":"2017","journal-title":"PLoS One"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000045113","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T11:02:45Z","timestamp":1779274965000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000045113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":48,"journal-issue":{"issue":"44","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000045113","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,31]]},"assertion":[{"value":"2025-07-13","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-08","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}